Vaxart (NASDAQ:VXRT) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
Earnings and Valuation
This table compares Vaxart and Genetic Technologies’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vaxart||$4.16 million||2.65||-$18.00 million||($2.65)||-0.26|
|Genetic Technologies||$140,000.00||74.29||-$4.23 million||N/A||N/A|
Insider & Institutional Ownership
4.6% of Vaxart shares are owned by institutional investors. Comparatively, 3.9% of Genetic Technologies shares are owned by institutional investors. 7.3% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent ratings and recommmendations for Vaxart and Genetic Technologies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Vaxart currently has a consensus price target of $2.00, indicating a potential upside of 186.12%. Given Vaxart’s higher possible upside, equities research analysts clearly believe Vaxart is more favorable than Genetic Technologies.
This table compares Vaxart and Genetic Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Vaxart has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Genetic Technologies has a beta of 3.54, meaning that its stock price is 254% more volatile than the S&P 500.
Genetic Technologies beats Vaxart on 6 of the 11 factors compared between the two stocks.
Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
About Genetic Technologies
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.